文献速递淋巴瘤

霍奇金淋巴瘤健康相关生活质量问卷的国际验证:EORTC QLQ-HL27

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27.
PubMed 文献 · Blood Adv · 2023-01-01

该国际研究纳入12个国家381例确诊霍奇金淋巴瘤患者,验证EORTC QLQ-HL27问卷的心理测量学性质。验证性因子分析显示27个条目在4个量表上拟合可接受,重测信度、收敛效度、已知组比较和反应度分析均获满意结果。治疗中患者症状负担和疲劳高于已完成治疗者,而担忧健康与功能的比例两组相似。

要点

  • EORTC QLQ-HL27含27个条目、4个量表:症状负担、身体状况/疲劳、情感影响、对健康/功能的担忧。
  • 治疗中患者报告至少有一些问题的比例:症状负担和疲劳为36%-83%,已完成治疗者为19%-61%。
  • 治疗中患者报告至少有一些担忧的比例为51%-81%,已完成治疗者为52%-78%。

核心结论

  • EORTC QLQ-HL27在国际样本中显示出可接受的心理测量学性质,用于研究和临床可提高霍奇金淋巴瘤患者健康相关生活质量评估的敏感性。

研究设计与样本

  • 国际多中心研究,纳入12个国家381例确诊霍奇金淋巴瘤患者,基线完成EORTC QLQ-C30、QLQ-HL27及汇报问卷。
  • 其中126例完成重测,98例完成反应度变化分析第二次测量。

主要发现

  • 验证性因子分析显示27个条目在4个量表上拟合可接受。
  • 重测信度、收敛效度、已知组比较和反应度变化分析均获满意结果。
  • 治疗中患者症状负担和疲劳高于已完成治疗者:报告至少有一些问题的比例分别为36%-83% vs 19%-61%。
  • 对健康与功能担忧(报告至少有一些担忧)的患病率在治疗中患者为51%-81%,已完成治疗者为52%-78%,两组相似。

关键数值与推荐

  • EORTC QLQ-HL27包含27个条目,归纳为4个量表:症状负担、身体状况/疲劳、情感影响、对健康/功能的担忧。

临床怎么用

  • 原文指出,在研究和临床应用中实施EORTC QLQ-HL27将提高霍奇金淋巴瘤患者健康相关生活质量评估的敏感性。
  • 原文预期通过使用该问卷产生的高质量数据将促进霍奇金淋巴瘤 setting 的临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hodgkin lymphoma (HL) has become 1 of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support informed clinical decisions. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group previously developed the EORTC Quality of Life Questionnaire (QLQ) Hodgkin Lymphoma 27. This paper reports the final results of an international study by the EORTC group to develop a HRQoL disease-specific measure for these patients: the EORTC QLQ-HL27. Patients with a confirmed diagnosis of HL (N = 381) were enrolled from 12 countries and completed the EORTC QLQ-C30, QLQ-HL27, and a debriefing questionnaire at baseline (any time after diagnosis). A subset completed a retest (n = 126) or responsiveness-to-change analyses (RCA) second measurement (n = 98). Psychometrics were evaluated. Confirmatory factor analysis showed an acceptable fit of the 27 items of the QLQ-HL27 on its 4 scales (symptom burden, physical condition/fatigue, emotional impact, and worries about health/functioning). Test-retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results. Symptom burden and fatigue was higher among patients on treatment (with 36%-83% reporting at least a few problems) compared with those who had completed treatment (19%-61% reporting at least a few problems). Prevalence of worries about health and functioning (reporting at least some worry) was similar for patients on treatment (51%-81%) vs those who had completed treatment (52%-78%). Implementation of the EORTC QLQ-HL27 in research and clinical applications will increase sensitivity of HRQoL assessment in patients with HL. High quality data generated through use of this questionnaire are expected to facilitate clinical decision making in the HL setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Oerlemans S, Efficace F, Shamieh O, et al. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27. Blood Adv. 2023. PMID: 37738090. doi:10.1182/bloodadvances.2023010841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。